STAT5A is a signal transduction and transcription factor that mediates cellular responses to multiple cytokines and growth factors, including stem cell factor, fibroblast growth factors, erythropoietin, and interleukins (IL-2, IL-3, IL-4, IL-5, IL-7, IL-9, IL-15). Upon cytokine stimulation, STAT5A becomes phosphorylated, dimerizes with STAT5B or itself, and translocates to the nucleus where it binds GAS regulatory elements to activate target genes 1. STAT5A regulates diverse physiological processes including T cell development, eosinophil differentiation, and milk protein expression during lactation. In disease contexts, hyperactivated STAT5A drives multiple cancers through distinct mechanisms. In T cell acute lymphoblastic leukemia, mutations causing STAT5A hyperactivity hijack T cell receptor signaling to promote immature T cell transformation; these tumors respond to STAT3/5 degraders and ZAP70 tyrosine kinase inhibitors 2. In ovarian cancer, STAT5A regulates the CypA/TAF15/miR-514a-3p feedback loop to promote epithelial-mesenchymal transition and metastasis 3. In gastric cancer, STAT5A upregulates CD44 to enhance proliferation and invasion 4. In glioblastoma, exosomal circRNA activates STAT5A to promote vasculogenic mimicry 5. However, STAT5A expression is significantly underexpressed in breast, lung, and ovarian cancers, where high expression correlates with favorable survival 6. In relapsing-remitting multiple sclerosis, STAT5A expression is downregulated, suggesting dysregulation of immune responses 7. STAT5A has emerged as a therapeutic target; selective STAT5A/5B inhibitors such as Stafiba are in development 8.